PE20070435A1 - Formulacion farmaceutica que comprende temozolomida y un inhibidor de la proteina quinasa - Google Patents
Formulacion farmaceutica que comprende temozolomida y un inhibidor de la proteina quinasaInfo
- Publication number
- PE20070435A1 PE20070435A1 PE2006001126A PE2006001126A PE20070435A1 PE 20070435 A1 PE20070435 A1 PE 20070435A1 PE 2006001126 A PE2006001126 A PE 2006001126A PE 2006001126 A PE2006001126 A PE 2006001126A PE 20070435 A1 PE20070435 A1 PE 20070435A1
- Authority
- PE
- Peru
- Prior art keywords
- prostama
- cancer
- protein kinase
- pharmaceutical formulation
- inhibitor
- Prior art date
Links
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004964 temozolomide Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 3
- ZCBUQCWBWNUWSU-SFHVURJKSA-N ruboxistaurin Chemical compound O=C1NC(=O)C2=C1C(C1=CC=CC=C11)=CN1CCO[C@H](CN(C)C)CCN1C3=CC=CC=C3C2=C1 ZCBUQCWBWNUWSU-SFHVURJKSA-N 0.000 abstract 3
- 102000003923 Protein Kinase C Human genes 0.000 abstract 2
- 108090000315 Protein Kinase C Proteins 0.000 abstract 2
- AXRCEOKUDYDWLF-UHFFFAOYSA-N 3-(1-methyl-3-indolyl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-3-indolyl]pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C(C1=CC=CC=C11)=CN1C(CC1)CCN1CC1=CC=CC=N1 AXRCEOKUDYDWLF-UHFFFAOYSA-N 0.000 abstract 1
- 206010003571 Astrocytoma Diseases 0.000 abstract 1
- 208000032612 Glial tumor Diseases 0.000 abstract 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 229950000261 ruboxistaurin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA FORMULACION FARMACEUTICA QUE COMPRENDE: A) TEMOZOLOMIDA (TMZ) EN UNA INTENSIDAD DE DOSIS ESTANDAR O AUMENTADA, EN COMBINACION CON B) UN INHIBIDOR DE LA PROTEINA QUINASA C (PKC), PREFERENTEMENTE UN INHIBIDOR SELECTIVO DE LA PKC BETA TAL COMO: RUBOXISTAURINA (LY333531), O N-DESMETIL LY333531 ENCONTRANDOSE EN UNA CANTIDAD APROXIMADA DE 0,1 MG A 1,5 MG POR DIA POR KG DE PESO CORPORAL; ENZASTAURINA (LY317615), LY326020 ENCONTRANDOSE EN UNA CANTIDAD APROXIMADA DE 250 MG A 1000MG POR DIA; O LY379196. TAMBIEN SE REFIERE A UN KIT QUE COMPRENDE DICHA FORMULACION, EL CUAL ES UTIL PARA EL TRATAMIENTO DE ENFERMEDAD PROLIFERATIVA CELULAR TAL COMO GLIOMA TAL COMO ASTROCITOMA ANAPLASICO O GLIOBLASTOMA MULTIFORME, CANCER DE PROSTATA, PULMON, MAMA, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71801105P | 2005-09-16 | 2005-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070435A1 true PE20070435A1 (es) | 2007-06-13 |
Family
ID=37865608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001126A PE20070435A1 (es) | 2005-09-16 | 2006-09-15 | Formulacion farmaceutica que comprende temozolomida y un inhibidor de la proteina quinasa |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20070112053A1 (es) |
| EP (1) | EP1940395A2 (es) |
| JP (1) | JP2009508868A (es) |
| AR (1) | AR056517A1 (es) |
| CA (1) | CA2622867A1 (es) |
| PE (1) | PE20070435A1 (es) |
| TW (1) | TW200803849A (es) |
| WO (1) | WO2007033374A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011036676A2 (en) | 2009-09-23 | 2011-03-31 | Ashwini Nangia | Stable cocrystals of temozolomide |
| TWI386203B (zh) * | 2011-01-07 | 2013-02-21 | Univ China Medical | 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用 |
| US8933078B2 (en) | 2011-07-14 | 2015-01-13 | Research Cancer Institute Of America | Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances |
| JP6222608B2 (ja) | 2012-03-06 | 2017-11-01 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ | 膠芽腫のためのプロカスパーゼ併用療法 |
| KR20140087846A (ko) * | 2012-12-31 | 2014-07-09 | 주식회사 삼양바이오팜 | 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법 |
| US11369585B2 (en) | 2017-03-17 | 2022-06-28 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| EP3691632B1 (en) * | 2017-10-06 | 2025-01-01 | Research Cancer Institute of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| EP3710434A4 (en) | 2017-11-17 | 2021-07-28 | Research Cancer Institute of America | COMPOSITIONS, METHODS, SYSTEMS AND / OR KITS FOR THE PREVENTION AND / OR TREATMENT OF NEOPLASMS |
| AU2018368453B2 (en) | 2017-11-17 | 2024-05-30 | The Board Of Trustees Of The University Of Illinois | Cancer therapy by degrading dual MEK signaling |
| KR20210084442A (ko) | 2018-10-05 | 2021-07-07 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 포도막 흑색종 치료를 위한 병용 요법 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260291A (en) | 1981-08-24 | 1993-11-09 | Cancer Research Campaign Technology Limited | Tetrazine derivatives |
| US4937232A (en) | 1986-09-15 | 1990-06-26 | Duke University | Inhibition of protein kinase C by long-chain bases |
| IL89167A (en) | 1988-02-10 | 1994-02-27 | Hoffmann La Roche | Substituted pyrroles, their manufacture and pharmaceutical compositions containing them |
| DE3827974A1 (de) | 1988-08-18 | 1990-02-22 | Boehringer Mannheim Gmbh | Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen |
| US4990519A (en) | 1988-10-24 | 1991-02-05 | Merrell Dow Pharmaceuticals | Method of using quinolyloxazole-2-ones as proteinkinase C inhibitors |
| US5141957A (en) | 1990-11-02 | 1992-08-25 | Sphinx Pharmaceuticals Corporation | 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c |
| US5204370A (en) | 1990-11-05 | 1993-04-20 | Sphinx Pharmaceuticals Corporation | Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase C |
| US5216014A (en) | 1991-09-10 | 1993-06-01 | Sphinx Pharmaceuticals Corporation | Furo-coumarinsulfonamides as protein kinase C inhibitors |
| US5270310A (en) | 1991-12-13 | 1993-12-14 | Sphinx Pharmaceuticals Corporation | N-aminoalkyl amide inhibitors of protein kinase C |
| US5621101A (en) | 1992-07-24 | 1997-04-15 | Cephalon, Inc. | Protein kinase inhibitors for treatment of neurological disorders |
| US5461146A (en) | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
| EP0724562B1 (en) | 1993-10-18 | 1998-06-03 | Virginia Tech Intellectual Properties, Inc. | Synthesis of sphingosines |
| US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| US5545636A (en) | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
| US5481003A (en) | 1994-06-22 | 1996-01-02 | Eli Lilly And Company | Protein kinase C inhibitors |
| US5491242A (en) | 1994-06-22 | 1996-02-13 | Eli Lilly And Company | Protein kinase C inhibitors |
| US5616577A (en) | 1994-08-25 | 1997-04-01 | Smithkline Beecham Corporation | Protein Kinase C inhibitor |
| US6232299B1 (en) | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
| US5939098A (en) * | 1996-09-19 | 1999-08-17 | Schering Corporation | Cancer treatment with temozolomide |
| US7186740B2 (en) * | 2002-09-23 | 2007-03-06 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
| US20050148643A1 (en) * | 2003-08-19 | 2005-07-07 | Agouron Pharmaceuticals, Inc. | Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme |
-
2006
- 2006-09-15 EP EP06844172A patent/EP1940395A2/en not_active Withdrawn
- 2006-09-15 WO PCT/US2006/036072 patent/WO2007033374A2/en not_active Ceased
- 2006-09-15 US US11/522,207 patent/US20070112053A1/en not_active Abandoned
- 2006-09-15 JP JP2008531365A patent/JP2009508868A/ja not_active Withdrawn
- 2006-09-15 AR ARP060104055A patent/AR056517A1/es not_active Application Discontinuation
- 2006-09-15 CA CA002622867A patent/CA2622867A1/en not_active Abandoned
- 2006-09-15 TW TW095134248A patent/TW200803849A/zh unknown
- 2006-09-15 PE PE2006001126A patent/PE20070435A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1940395A2 (en) | 2008-07-09 |
| WO2007033374A2 (en) | 2007-03-22 |
| WO2007033374A3 (en) | 2007-07-26 |
| US20070112053A1 (en) | 2007-05-17 |
| TW200803849A (en) | 2008-01-16 |
| CA2622867A1 (en) | 2007-03-22 |
| JP2009508868A (ja) | 2009-03-05 |
| AR056517A1 (es) | 2007-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY27943A1 (es) | Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos | |
| AR052190A1 (es) | Uso de clorantes de cianina para el diagnostico de enfermedades proliferativas | |
| UY28213A1 (es) | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. | |
| AR073563A1 (es) | Terapia de combinacion para el tratamiento de diabetes y estados relacionados | |
| PE20080907A1 (es) | Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan | |
| SV2006002473A (es) | Forma cristalina ortorrombica del maleato de asenapina y su uso en el tratamiento de trastornos mentales ref. 2005.893 (806.671) | |
| CL2007000797A1 (es) | Composicion farmaceutica que comprende entre alrededor de 1 y 150 mg/ml de humab igf-1r, entre alrededor de 0,001 y 1% de al menos un humectante, entre alredededor de 1 y 100 mm de un tapon a un ph entre alrededor de 5 y 7; y uso para el tratamiento de cancer de mama, cancer de pulmon y de prostata | |
| EA200701094A1 (ru) | Усовершенствованное лечение рака с применением агонистов tlr3 | |
| ECSP044935A (es) | Inhibidores de la dipeptidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes | |
| CR6654A (es) | Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco | |
| UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
| GT200500260A (es) | Amidas biciclicas como inhibidores de cinasa. | |
| SV2007002146A (es) | Difenilimidazopirimidina e imidazol aminas como inhibidores de beta-secretasa ref. am101727 | |
| MX2010003815A (es) | Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2. | |
| CL2008001303A1 (es) | Compuestos derivados de heterociclos, moduladores de gamma secretasa; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento del alzheimer. | |
| AR048819A1 (es) | Metodos sinergicos y composiciones para el tratamiento del cancer | |
| CL2009001160A1 (es) | Compuestos derivados de heterociclos nitrogenados fusionados y su composicion farmaceutica. | |
| UA108618C2 (uk) | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| PE20070435A1 (es) | Formulacion farmaceutica que comprende temozolomida y un inhibidor de la proteina quinasa | |
| PE20010630A1 (es) | Uso de una composicion antialergica para el tratamiento de trastornos mentales | |
| DOP2009000208A (es) | Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana | |
| UY29249A1 (es) | Agentes citotóxicos que comprenden taxanos nuevos | |
| GT200500113A (es) | Derivados de pirimidina para tratar el crecimiento celular anomalo | |
| TW200503667A (en) | Therapeutic combinations | |
| PA8654201A1 (es) | Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |